Navigation Links
AutoImmune Inc. Announces Shareholder Approval of Plan of Complete Liquidation and Dissolution
Date:5/14/2010

PASADENA, Calif., May 14 /PRNewswire-FirstCall/ -- AutoImmune Inc. (Pink Sheets: AIMM) today announced that its stockholders have voted in favor of the company's voluntary dissolution pursuant to a Plan of Complete Liquidation and Dissolution at a special meeting of stockholders held on May 11, 2010.  Stockholders voted overwhelmingly in favor of the dissolution of the company pursuant to the Plan of Complete Liquidation and Dissolution, with the proposal receiving an affirmative vote from approximately 99% of the votes cast at the special meeting of stockholders.  AutoImmune's business activities will now be limited to those necessary to preserve the value of its assets, wind up its business and affairs, and distribute its assets in accordance with the Plan of Complete Liquidation and Dissolution.  AutoImmune intends to file a Certificate of Dissolution with the Secretary of State of Delaware and to commence the elective dissolution process under Delaware law.

About AutoImmune Inc.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Website: http://www.autoimmuneinc.com  


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
4. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
6. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
7. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
8. AutoImmune Inc. Reports 2009 First Quarter Financial Results
9. AutoImmune Inc. Reports 2009 Second Quarter Financial Results
10. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
11. RNL BIO Rescues a College Student from Autoimmune Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 30, 2020 , ... ... sciences industry, today announced the release of its signature product called Beacon ... Liaisons (MSLs) and other field medical professionals. , Beacon helps MSLs ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to ... Bioactives. “It’s the only technology of its kind on the market and we were ... with the protective capacity of traditional cultured ingredients, creating a natural way to extend ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode ... significant expansion of laboratory operations through its COVID-19 testing service, Bode-CARES . ... , Bode-CARES provides a turnkey solution that includes a comprehensive ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its ... the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as ...
Breaking Biology Technology:
(Date:8/26/2020)... ... August 25, 2020 , ... ... in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology and ... study of SkQ1 ophthalmic solution in patients with moderate to severe Dry ...
(Date:8/23/2020)... ... August 21, 2020 , ... ... has been published and is now available on the company’s global website. ... the X-ray analysis community, presenting current news and crystallographic research. , The ...
(Date:8/21/2020)... ... August 19, 2020 , ... The ... uniting life science, data science, informatics and IT leaders goes VIRTUAL and announces ... of uncertainty and change, Bio-IT takes the leadership role of keeping our life ...
Breaking Biology News(10 mins):